The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a regulatory information service, this information is in the public domain.
CelLBxHealth plc
(“CelLBxHealth” or "the Company")
CelLBxHealth signs Master Services Agreement with a Swiss biotech company for a
Radio-Pharmaceutical Clinical Study
Guildford, UK and Plymouth Meeting, U.S. - 21 October 2026 - CelLBxHealth plc (AIM: CLBX), a circulating tumour cell (CTC) intelligence company specialising in CTC solutions for use in research, drug development and clinical oncology, announces that it has entered into a Master Services Agreement (“MSA”), together with a Statement of Work, with a Swiss biotech company.
Dr. Jan Groen, Executive Chairman of CelLBxHealth, commented:
“We are pleased to support the programme. This study brings together our CTC enrichment and analysis capabilities with a targeted radio-pharmaceutical development programme. We aim to generate data that may help the Swiss biotech company explore the role of CTCs in its future research and clinical applications.”
In 2025, the market size of the radioligand-therapy market was had a value of ~ US$3.0 billion, increasing to between US$10.9 billion and US$15.9 billion by 2035, representing annual growth of approximately 13–18%. (source: SNS Inside pvt ltd).
For further information:
|
CelLBxHealth plc Jan Groen, Executive Chairman |
via Walbrook PR |
|
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales) |
+44 (0)20 7220 0500 |
|
Walbrook PR (Investor and Media Relations) Paul McManus / Alice Woodings |
Tel: +44 (0)20 7933 8780 or [email protected] Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
Notes for editors
About CelLBxHealth plc
CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows. Commercial focus span three revenue streams — Product Sales through CRO, clinical lab partnerships and laboratory services including clinical trial support and assay development.
For more information, visit https://cellbxhealth.com/.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.